159 related articles for article (PubMed ID: 9731491)
1. Effects of some novel inhibitors of C17,20-lyase and 5alpha-reductase in vitro and in vivo and their potential role in the treatment of prostate cancer.
Nnane IP; Kato K; Liu Y; Lu Q; Wang X; Ling YZ; Brodie A
Cancer Res; 1998 Sep; 58(17):3826-32. PubMed ID: 9731491
[TBL] [Abstract][Full Text] [Related]
2. LY207320 (6-methylene-4-pregnene-3,20-dione) inhibits testosterone biosynthesis, androgen uptake, 5 alpha-reductase, and produces prostatic regression in male rats.
Neubauer BL; Best KL; Blohm TR; Gates C; Goode RL; Hirsch KS; Laughlin ME; Petrow V; Smalstig EB; Stamm NB
Prostate; 1993; 23(3):181-99. PubMed ID: 8234065
[TBL] [Abstract][Full Text] [Related]
3. CGP 53153: a new potent inhibitor of 5alpha-reductase.
Häusler A; Allegrini PR; Biollaz M; Batzl C; Scheidegger E; Bhatnagar AS
J Steroid Biochem Mol Biol; 1996 Feb; 57(3-4):187-95. PubMed ID: 8645628
[TBL] [Abstract][Full Text] [Related]
4. 4-pregnene-3-one-20 beta-carboxaldehyde: a potent inhibitor of 17 alpha-hydroxylase/C17,20-lyase and of 5 alpha-reductase.
Li J; Li Y; Son C; Banks P; Brodie A
J Steroid Biochem Mol Biol; 1992 May; 42(3-4):313-20. PubMed ID: 1606043
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of androgen synthesis by 22-hydroximino-23,24-bisnor-4-cholen-3-one.
Li J; Li Y; Son C; Brodie AM
Prostate; 1995 Mar; 26(3):140-50. PubMed ID: 7534917
[TBL] [Abstract][Full Text] [Related]
6. Effects of 5 alpha-reductase inhibitors on intraprostatic androgens in the rat.
di Salle E; Giudici D; Biagini L; Cominato C; Briatico G; Panzeri A
J Steroid Biochem Mol Biol; 1995 Jun; 53(1-6):381-5. PubMed ID: 7626485
[TBL] [Abstract][Full Text] [Related]
7. 5alpha-reductase inhibitors/finasteride.
Stoner E
Prostate Suppl; 1996; 6():82-7. PubMed ID: 8630236
[TBL] [Abstract][Full Text] [Related]
8. Prostatic involution in rats induced by a novel 5 alpha-reductase inhibitor, SK&F 105657: role for testosterone in the androgenic response.
Lamb JC; English H; Levandoski PL; Rhodes GR; Johnson RK; Isaacs JT
Endocrinology; 1992 Feb; 130(2):685-94. PubMed ID: 1733716
[TBL] [Abstract][Full Text] [Related]
9. Androgens are not major down-regulators of androgen receptor levels during growth of the immature rat penis .
Shen R; Lin MC; Sadeghi F; Swerdloff RS; Rajfer J; Gonzalez-Cadavid NF
J Steroid Biochem Mol Biol; 1996 Mar; 57(5-6):301-13. PubMed ID: 8639466
[TBL] [Abstract][Full Text] [Related]
10. Responses of LNCaP prostatic adenocarcinoma cell cultures to LY300502, a benzoquinolinone human type I 5alpha-reductase inhibitor.
Sutkowski DM; Audia JE; Goode RL; Hsiao KC; Leibovitch IY; McNulty AM; Neubauer BL
Prostate Suppl; 1996; 6():62-6. PubMed ID: 8630232
[TBL] [Abstract][Full Text] [Related]
11. Endocrine and antiprostatic effects of raloxifene (LY156758) in the male rat.
Neubauer BL; Best KL; Clemens JA; Gates CA; Goode RL; Jones CD; Laughlin ME; Shaar CJ; Toomey RE; Hoover DM
Prostate; 1993; 23(3):245-62. PubMed ID: 8234067
[TBL] [Abstract][Full Text] [Related]
12. Hormonal effects of turosteride, a 5 alpha-reductase inhibitor, in the rat.
di Salle E; Giudici D; Briatico G; Ornati G; Panzeri A
J Steroid Biochem Mol Biol; 1993 Nov; 46(5):549-55. PubMed ID: 8240976
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of new specific azasteroid inhibitors of steroid 5 alpha-reductase on canine hyperplastic prostate: suppression of prostatic DHT correlated with prostate regression.
Cohen SM; Werrmann JG; Rasmusson GH; Tanaka WK; Malatesta PF; Prahalada S; Jacobs JG; Harris G; Nett TM
Prostate; 1995 Feb; 26(2):55-71. PubMed ID: 7531846
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and in vitro activity of 17 beta-(N-alkyl/arylformamido)- and 17 beta-[(N-alkyl/aryl)alkyl/arylamido]-4-methyl-4-aza-3-oxo-5 alpha-androstan-3-ones as inhibitors of human 5 alpha-reductases and antagonists of the androgen receptor.
Li X; Singh SM; Labrie F
J Med Chem; 1995 Mar; 38(7):1158-73. PubMed ID: 7707319
[TBL] [Abstract][Full Text] [Related]
15. Potential activities of androgen metabolizing enzymes in human prostate.
Krieg M; Weisser H; Tunn S
J Steroid Biochem Mol Biol; 1995 Jun; 53(1-6):395-400. PubMed ID: 7542902
[TBL] [Abstract][Full Text] [Related]
16. Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17,20-lyase (cytochrome P45017 alpha) with resistance to esterase hydrolysis.
Rowlands MG; Barrie SE; Chan F; Houghton J; Jarman M; McCague R; Potter GA
J Med Chem; 1995 Oct; 38(21):4191-7. PubMed ID: 7473546
[TBL] [Abstract][Full Text] [Related]
17. FK143, a novel nonsteroidal inhibitor of steroid 5 alpha-reductase: (2) In vivo effects on rat and dog prostates.
Hirosumi J; Nakayama O; Chida N; Inami M; Fagan T; Sawada K; Shigematsu S; Kojo H; Notsu Y; Okuhara M
J Steroid Biochem Mol Biol; 1995 Apr; 52(4):365-73. PubMed ID: 7734405
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase).
Barrie SE; Potter GA; Goddard PM; Haynes BP; Dowsett M; Jarman M
J Steroid Biochem Mol Biol; 1994 Sep; 50(5-6):267-73. PubMed ID: 7918112
[TBL] [Abstract][Full Text] [Related]
19. FK143, a novel nonsteroidal inhibitor of steroid 5 alpha-reductase: (1) In vitro effects on human and animal prostatic enzymes.
Hirosumi J; Nakayama O; Fagan T; Sawada K; Chida N; Inami M; Takahashi S; Kojo H; Notsu Y; Okuhara M
J Steroid Biochem Mol Biol; 1995 Apr; 52(4):357-63. PubMed ID: 7734404
[TBL] [Abstract][Full Text] [Related]
20. Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition.
Rhodes L; Primka RL; Berman C; Vergult G; Gabriel M; Pierre-Malice M; Gibelin B
Prostate; 1993; 22(1):43-51. PubMed ID: 8381228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
